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Staging of cervical cancer is routinely performed by means of 
examination under anesthesia in combination with radiographic 
and/or endoscopic techniques. This "clinical” staging leads to 10- 
25% misclassification, mostly due to positive lymph nodes or 
lymph or blood vessel invasion. Determination of pretreatment 
squamous cell carcinoma antigen (SCC) and CA 125 serum levels 
may solve part of this staging problem and may improve the selec­
tion o f  the most appropriate individual therapy. Using 2.5 ng/ml 
(SCC) and 35 U/ml (CA 125) as cutoff levels, we studied 99 pa­
riente retrospectively. Elevated levels were found in 27% (SCC) 
and 23% (CA 125). In clinical stage IB or IIA disease 45/81 patients 
had positive nodes or lymph or blood vessel invasion at operation. 
Of these patients 49% had elevated serum levels of SCC or CA 
125. Strongest correlation was found with blood vessel invasion 
(57%). Only 19% of low-stage patients without evidence of vascular 
spread of disease had positive levels. The positive predictive value 
of SCC and CA 125 for detection of vascular spread of disease in 
low-stage cervical cancer was 76%. In most centers surgery is the 
primary treatment of choice in low-stage cervical cancer. Never­
theless, with respect to patient survival, results of primary surgery 
and primary radiotherapy are comparable. Radiotherapy given in 
an adjuvant setting leads to a high incidence of severe complica­
tions. In order to overcome part of these complications one should 
consider radiotherapy as the primary therapy of choice in patients 
with clinical stage IB or IIA cervical cancer with elevated pretreat­
ment SCC or CA 125 levels. © 1997 Academic Press
INTRODUCTION
T um or staging is one of the most important aspects in the 
treatment of patients with oncological diseases. The type of 
treatment offered to a patient largely depends on the exten­
sion o f  the disease. Misclassification of stage may thus result 
in a suboptimal therapeutic approach. In most malignancies 
the stage of disease is defined following (extensive) surgery 
and histopathologic examination of all tissues removed. 
However, in the case of cervical cancer, staging of the dis­
ease is routinely performed by means of examination under
anesthesia in combination with radiographic and/or endo­
scopic techniques. This type of staging is referred to as 
“ clinical staging/’ The main reason for this clinical estima­
tion of the extent of disease is the fact that in most centers 
radiotherapy is the primary treatment of choice for patients 
with locally advanced disease, In these cases a surgical inter­
vention should be prevented since it may reduce the effec­
tiveness of the additional radiation treatment and lead to a 
higher incidence of severe complications [1]. Examination 
under anesthesia is surely not a very accurate way to evaluate 
a patient’s extent of disease. Especially, tumor spread be­
yond the small pelvis or lymph and blood vessel invasion 
cannot be detected with this type of staging. When clinical 
staging was compared with surgical staging, inaccuracies 
(mostly understaging) were found in 10-25% of patients 
with clinical stage IB or IIA [2—4]. Several authors have 
demonstrated reduced survival in patients with lymph node 
metastases and lymph or blood vessel invasion [5, 6], It 
seems useful to develop new strategies to define subgroups 
of patients in order to further individualize treatment.
During the past decade a number of potentially useful 
serum tumor markers have been developed. Squamous cell 
carcinoma antigen (SCC) is a subfraction of the tumor anti­
gen TA-4 and was isolated from a squamous cell carcinoma 
of the uterine cervix [7]. In prior studies of patients with 
squamous cell carcinoma of the cervix, SCC serum levels 
have been shown to correlate with stage of disease, to be 
predictive of response, and to aid in the detection of recur­
rence [8-10]. CA 125 is a tumor marker mainly used for 
the monitoring of treatment results in patients with ovarian 
cancer. However, the CA 125 antigenic determinant has also 
been reported to be present on adenocarcinoma of the endo- 
cervix. CA 125 serum levels were elevated in 50% of the 
patients with cervical adenocarcinoma [11].
The present study retrospectively analyzed the correlation 
between the serum levels of SCC and CA 125 and the post­
surgery-determined extent of disease in patients with cervi­
cal cancer. Special attention was given to the predictability
473 0090-8258/97 $25.00 
Copyright © 1997 by Academic Press 
All rights of reproduction in any form reserved.
474 MASSUGER ET AL.
TABLE 1
Correlation between Stage of Cervical Cancer and Pretreatment




CA 125 (U/ml) 
median (range)
Stage I 63 1.6 (0.4-15) 15.0 (2.0-210)
Stage II 28 1.6 (0.5-34) 17.0 (3.8-910)
Stage III/IV 8 18.0 (0.6-70) 17.0 (9.7-1300)
All patients 99 1.7 (0.4-70) 15.0 (2.0-1300)
of positive lymph nodes and/or vascular spread of disease 
in clinical stage IB and IIA cervical carcinoma. Thus, it was 
questioned whether determination of SCC and CA 125 serum 
levels can contribute to the selection of the most appropriate 
individual therapy.
MATERIALS AND METHODS
Medical records of 99 patients with histopathologically 
proven cervical cancer were studied. All patients attended 
the Department of Obstetrics and Gynecology of the Univer­
sity Hospital Nijmegen between 1983 and 1994. The ages 
of the 99 patients ranged from 20 to 81 years, median 41 
years. Patients were clinically staged according to interna­
tional FIGO (International Federation of Gynecology and 
Obstetrics) guidelines. Staging was routinely performed by 
means of examination under anesthesia in combination with 
radiographic and/or endoscopic techniques. The clinical 
stage of disease was FIGO stage IB in 63, IIA in 18, IIB in 
10, III in 6, and IV in 2 patients. All the patients with stage 
IB or IIA and 3 patients with stage IIB were treated with 
radical surgery including retroperitoneal para-aortic and pel­
vic lymph node dissection. Overall, a median number of 24 
lymph nodes were removed at operation. Patients that were 
not primarily operated received radiotherapy (N =*= 15), All 
patients with lymph node metastases, vascular invasion, and/ 
or histopathologically positive resection margins received 
postoperative radiotherapy.
Pretreatment blood samples were drawn from each patient 
within 2 weeks before primary therapy and stored at -35°C 
until assayed. All the serum specimens were assayed for 
SCC and CA 125. The SCC antigen was measured using 
a microparticle enzyme immunoassay (IMx SCC; Abbott 
Laboratories, Diagnostic Division, Abbott Park, IL). A value 
of 2.5 ng/ml was chosen as the upper limit of normal. This 
cutoff level represents the 99th percentile in a group of 885 
healthy subjects (data provided by manufacturer). CA 125 
measurements were performed with the IMx CA 125 (Abbott 
Laboratories, Diagnostic Division). For this assay the inter­
nationally used cutoff level of 35 U/ml was chosen, being the 
99th percentile in a normal population. Pretreatment serum 
values for SCC and CA 125 were compared with several
TABLE 2
SCC and CA 125 Pretreatment Serum Levels in Relation to 
Histopathological Diagnosis (Numbers above Indicated Cutoff)
N
SCC >  2.5 
(ng/ml)
CA 125 >  35 
(U/ml)
Squamous cell carcinoma 67 19 (28%) 13 (19%)
Adenocarcinoma 20 4 (20%) 6 (30%)
Adenosquamous carcinoma 8 2 (25%) 2 (25%)
Others 4 1 (25%) 2 (50%)
All patients 99 26 (26%) 23 (23%)
clinical and histopathological. parameters. Statistical analysis 
was performed using the Wilcoxon rank-sum  test for com­
parison of the serum marker concentrations. The %2 test was 
used to investigate differences in the number of patients with 
elevated marker levels between subgroups.
RESULTS
Overall, elevated pretreatment levels of SCC and CA 125 
were found in only 26 and 23% of all patients (N = 99), 
respectively. The combined use of both tumor markers re­
sulted in positive values for one or both markers in 42% of 
the patients. Median pretreatment levels of CA 125 were in 
the same range for all clinical stages (15 U/ml), with a wide 
variation in each stage (Table 1). Median values for SCC 
were in the same range for stage I and II patients. However, 
significantly higher median values for SCC were found in 
advanced stage (III and IV) cervical cancer (Wilcoxon test: 
P = 0.008). In the subgroup of patients with squamous cell 
carcinoma (N =  67) elevated SCC levels were found in 28%, 
whereas CA 125 levels were elevated in only 19% of these 
patients (Table 2). In patients with adenocarcinoma (N = 
20) CA 125 levels were elevated in 30% of the patients with 
SCC values being elevated in 20%. In only one patient tumor 
cell differentiation was reported to be grade 1. Elevated SCC 
levels were found in 26% of the cases with grade 2 and in 
32% of the grade 3 cases (Table 3). This difference was 
not statistically significant (%2: P — 0.52). For CA 125 the 
difference was even smaller (20% for grade 2 and 27% for
TABLE 3
SCC and CA 125 Pretreatment Serum Levels in Relation to 
Differentiation (Numbers above Indicated Cutoff)
Differentiation N
SCC >  2.5
ng/ml
CA 125 >  35 
U/ml
1 1 1 0
2 54 14 (26%) 11 (20%)
3 34 11 (32%) 9 (27%)
Unknown 10 0 3 (30%)
All patients 99 26 (26%) 23 (23%)
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TABLE 4
SCC and CA 125 Pretreatment Serum Levels in Relation to 
Tumor Size in 81 Patients with Stage IB and IIA Cervical Cancer 
(Median Value and Range)
N SCC (ng/ml) CA 125 (U/ml)
< 2  cm 23 1.6 (0.6-3.1) 13 (3.5-50)
> 2  cm 54 1.5 (0.4-15) 17 (2.0-210)
Unknown 4 2,5 (0.9-7.3) 12 (5.6-27)
grade 3). The correlation between tumor size and pretreat­
ment serum levels of both markers was studied in the group 
of patients with stage IB or IIA (N = 81). Median levels for 
tumors less than 2 cm in diameter were in the same range 
for both markers used, when compared with larger tumors
(Table 4).
In the subgroup of patients with (clinical) stage IB and 
1IA (TV =  81) 45 patients were found to have some histopath- 
ological evidence of vascular spread of tumor cells. Of these 
patients 13 (16%) were found to have positive lymph nodes. 
Thirty-three patients (41%) had invasion of lymph vessels, 
whereas 23 patients (28%) had signs of blood vessel inva­
sion. Among the 13 patients with nodal disease only 1 patient 
had positive periaortic or common iliac nodes (1.2% of all 
stage IB and IIA patients). In this patient elevated serum 
levels were found for both markers. Overall, 22 of 45 patients 
(49%) with evidence of vascular (lymph or blood vessel) 
spread or nodal disease had pretreatment elevated serum 
levels of SCC or CA 125 (Table 5). Strongest correlation 
with elevated marker levels was found in the group with 
blood vessel invasion (57%). In the group with lymph vessel 
invasion 55% had positive levels of either SCC or CA 125, 
whereas in the group with positive lymph nodes 46% had 
positive levels. Of the stage IB and IIA patients with no 
evidence of vascular spread of tumor cells, only 19% (7/36) 
had positive serum levels. These data resulted in a positive 
predictive value of 76% (22/29) for the detection of some 
type of vascular spread in stage IB or IIA patients.
Progressive disease after primary treatment in patients
with (clinical) stage IB or IIA was observed in 27% (N = 
22) of the cases. Progression occurred between 1.4 and 104 
months (median 10 months) after radical hysterectomy. Most 
of these patients (81.8%) had positive lymph nodes and/or 
lymph or blood vessel invasion at the time of radical surgery. 
Progressive disease was found in 56% of patients with ele­
vated pretreatment CA 125 levels (N = 16), whereas only 
19% of the patients with elevated SCC levels (N = 16) 
demonstrated progression.
DISCUSSION
The internationally accepted FIGO classification of cervi­
cal cancer, based on clinical staging, is an inaccurate way 
of defining a patient’s extent of disease. This noninvasive 
approach leads to misclassification (mostly understaging) in 
a considerable number of cases (10-25%), possibly resulting 
in suboptimal care [2-4], Patients with positive lymph nodes 
and/or clear lymph or blood vessel invasion comprise most 
of the misclassified cases. Most of these patients need adju­
vant radiation treatment leading to a higher incidence of 
severe complications. Determination of pretreatment serum 
levels of tumor-associated antigens may help to improve the 
selection of the most appropriate therapy regimen for an 
individual patient. A panel of SCC and CA 125 was chosen 
to cover squamous as well as aclenocarcinomatous type of 
cervical carcinoma. Following the recommendations of the 
manufacturer 2.5 ng/ml was chosen as a cutoff level for SCC 
leading to a specificity of 99%. When this value was used 
in other studies elevated serum levels were found in 4 4 -  
57% of patients with cervical cancer [8, 9]. In our study the 
sensitivity of this marker for cervical cancer was only 26%, 
probably as a result of the relatively high number of low- 
stage patients (82% stage IB or IIA). In concordance with 
the results of Avall-Lundqvist et aL [9] serum CA 125 was 
elevated in only 23% of the patients. These results confirm 
that both SCC and CA 125 are not suitable for the primary 
detection (screening) of patients with cervical cancer.
Median serum levels of SCC were the same for stage I 
and stage II patients (Table 1). However, as found by others
TABLE 5
Correlation between SCC and CA 125 Serum Levels and Vascular Invasion in Patients (N  = 81)
with Stage IB and IIA (Numbers above Indicated Cutoff)
N SCC >  2.5 (ng/ml) CA 125 >  35 (U/ml) Either
Lymph nodes (+) 13 2 (15%)
m
5 (39%) 6 (46%)
Lymph nodes ( - ) 68 14 (21%) 11 (16%) 23 (34%)
Lymph vessel (+) 33 10 (30%) 11 (33%) 18 (55%)
Lymph vessel ( - ) 48 6 (13%) 5 (10%) 11 (23%)
Blood vessel (+) 23 7 (30%) 8 (35%) 13 (57%)
Blood vessel ( - ) 58 9 (16%) 8 (14%) 16 (28%)
Lymph node (-I-) and/or vascular invasion (-f-) 45 12 (27%) 13 (29%) 22 (49%)
Lymph node (~ ) and vascular invasion (—) 36 4 (11%) 3 (8.3%) 7 (19%)
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[9, 12] significantly higher SCC levels were found for stage 
III and IV. The relatively small tumor bulk and the limited 
degree of infiltration may explain low marker levels in low- 
stage patients. In case of CA 125 the median levels were 
not stage dependent. In contrast with the results of Duk et 
al  [8], we did not find a correlation between tumor size and 
marker levels in a subpopulation of stage IB and IIA patients. 
Unlike SCC, the serum CA 125 level was found to be a 
useful indicator for progression. Of all 16 patients with stage 
IB and IIA disease who had pretreatment CA 125 levels 
>35 U/ml, 9 patients (56%) demonstrated progression dur­
ing follow-up.
Of the group of stage IB and IIA (N ~  81), 45 patients 
were found to have lymph node metastases or lymph or 
blood vessel invasion. These data are in line with other 
studies. Overall, 49% of these patients had elevated pretreat­
ment SCC or CA 125 levels. On the other hand only 19% 
of patients without evidence of vascular spread had elevated 
serum levels. Thus, a panel of SCC and CA 125 seems to 
be a useful marker in predicting the presence of vascular 
spread of disease. However, in 1 of 5 patients without tumor 
spread a false positive prediction will be made. Of all stage 
IB and IIA patients with positive pretreatment values (N = 
29) 22 patients were found to have vascular tumor spread 
resulting in a positive predictive value of 76%. At present 
results of primary surgery on the one hand and radiotherapy 
on the other as the primary treatment modality in low-stage 
cervical cancer are comparable. Since postoperative radio­
therapy leads to a higher incidence of severe complications 
one should consider radiation treatment as the primary treat­
ment of choice in stage IB and IIA cervical cancer patients 
with elevated SCC and or CA 125 serum levels.
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